Nasdaq:MASI
MASIMO CORP
A leader in non-invasive patient monitoring offering probe-less oxygen saturation measurement technology to hospitals and home care providers.
Key Metrics
Investment Thesis
Bull Case
Investors should consider MASIMO for its unmatched market leadership in non-invasive monitoring and the recurring revenue potential from its subscription-based sensor business model. The company's strong operating cash flow generation and dominant market share suggest resilience against economic downturns that might affect discretionary healthcare spending. Acquiring a stake offers exposure to the growing demand for remote patient monitoring solutions as healthcare systems shift toward home care models.
Bear Case
The stock faces immediate headwinds from substantial recent net losses and a significant reduction in cash on hand due to heavy debt repayments and share buybacks that limit financial flexibility. Discontinued operations contributed heavily to the bottom line, creating uncertainty about whether reported earnings will normalize or if further restructuring charges are needed. High valuation multiples often apply to healthcare tech leaders, making the stock vulnerable to corrections if growth rates decelerate or regulatory hurdles arise.
About MASIMO CORP
MASIMO Corp designs, manufactures, and markets advanced patient monitoring systems that measure oxygen saturation without requiring a physical probe on the fingertip. Operating primarily in the United States, these non-invasive sensors are critical for hospitals, home care settings, and ambulances to track patient health in real-time. The company serves acute care facilities, post-acute providers, and distributors across North America with its proprietary pulse oximetry technology.
Analysis
Management Discussion
While operating profit remains healthy at $310.0M, the net loss is primarily driven by a $359.2M charge from discontinued operations and aggressive share repurchases totaling $363.7M that reduced cash reserves significantly. The company generated strong operating cash flow of $217.8M, indicating underlying business strength despite the accounting losses associated with exiting specific legacy lines or strategic restructuring. Management is focusing on capital efficiency by retiring revolver debt of $1.28B while maintaining substantial investments in R&D to defend their technological moat.
Industry Overview
The patient monitoring sector is experiencing rapid growth driven by an aging population and the urgent need for cost-effective solutions in hospital-at-home programs. Competition is intensifying as traditional probe-based competitors attempt to catch up with non-invasive technologies, yet MASIMO maintains a substantial lead through proprietary algorithms and extensive clinical validation data. Regulatory bodies continue to tighten standards for medical device accuracy, which favors established players like MASIMO that have decades of real-world performance data to support their claims.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|
| Revenue | $2.04B | $2.05B | $2.09B | $1.53B |
| Cost of Revenue | $977.0M | $1.04B | $1.09B | $581.7M |
| Gross Profit | $1.06B | $1.00B | $1.00B | $945.2M |
| Operating Expenses | $848.8M | $867.0M | $1.27B | $635.2M |
| Operating Income | $210.0M | $136.5M | $-266.7M | $310.0M |
| R&D | $191.4M | $175.2M | $222.8M | $126.4M |
| G&A | $657.4M | $664.0M | $743.8M | $506.0M |
| Stock-Based Comp | $47.7M | $7.0M | $41.5M | $35.8M |
| D&A | $136.1M | $98.3M | $103.0M | $38.8M |
| Depreciation | $43.0M | $43.9M | $41.3M | — |
| Other OpEx | $0 | $27.8M | $304.5M | $2.8M |
| Non-Operating Income | $-16.6M | $-48.4M | $-38.6M | $-37.4M |
| Interest Expense | $25.7M | $50.3M | — | — |
| Interest Income | $1.8M | $3.0M | $4.8M | $3.4M |
| Pre-Tax Income | $193.4M | $88.1M | $-305.3M | $272.6M |
| Income Tax | $49.9M | $6.6M | $-400.0K | $64.9M |
| Continuing Ops | $143.5M | $81.5M | $-304.9M | $207.7M |
| Discontinued Ops | $0 | $0 | $0 | $-359.2M |
| Net Income | $143.5M | $81.5M | $-304.9M | $-151.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $143.5M | $81.5M | $-304.9M | $-151.5M |
| Metric | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|
| Current Assets | $1.31B | $1.23B | $1.23B | $926.0M |
| Cash & Equivalents | $202.9M | $163.0M | $177.6M | $152.3M |
| Accounts Receivable | — | $355.5M | — | $275.8M |
| Inventory | $501.0M | $545.0M | $459.2M | $380.3M |
| Other Current Assets | $604.7M | $168.4M | $589.0M | $117.6M |
| Long-Term Assets | $1.90B | $1.81B | $1.40B | $772.9M |
| PP&E (Net) | $402.5M | $424.4M | $381.6M | $355.1M |
| Intangibles | $722.6M | $652.3M | $558.2M | — |
| Goodwill | $445.4M | $407.7M | $96.7M | $101.0M |
| Operating Leases | $69.6M | $59.1M | $74.4M | $32.6M |
| Other LT Assets | $248.1M | $258.9M | $282.4M | $278.3M |
| Total Assets | $3.21B | $3.04B | $2.63B | $1.70B |
| Current Liabilities | $630.0M | $563.8M | $617.7M | $371.6M |
| Accounts Payable | $276.8M | $251.5M | $252.8M | $103.0M |
| Current Debt | $15.1M | $34.3M | $37.3M | $6.3M |
| Current Leases | $18.7M | $18.2M | $21.4M | $8.1M |
| Deferred Revenue | $80.6M | $87.3M | $95.5M | $73.2M |
| Taxes Payable | $32.1M | $16.1M | $18.4M | $16.7M |
| Other Current Liab | $166.8M | $130.1M | $161.3M | $155.2M |
| Long-Term Liabilities | $1.24B | $1.11B | $956.1M | $606.1M |
| Long-Term Debt | $941.6M | $871.7M | $727.9M | $518.0M |
| LT Operating Leases | $53.4M | $45.8M | $59.5M | $26.9M |
| Other LT Liab | $213.5M | $160.6M | $141.3M | $38.2M |
| Total Liabilities | $1.87B | $1.68B | $1.57B | $977.7M |
| Shareholders' Equity | $1.34B | $1.36B | $1.05B | $721.2M |
| Paid-In Capital | $782.2M | $783.4M | $838.3M | $929.1M |
| Retained Earnings | $1.71B | $1.80B | $1.49B | $1.34B |
| Treasury Stock | $1.17B | — | — | — |
| Total L&E | $3.21B | $3.04B | $2.63B | $1.70B |
| Metric | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|
| Net Income (CFO) | $143.5M | $81.5M | $-304.9M | $-151.5M |
| Non-Cash Adjustments | $-505.3M | $87.2M | $364.5M | $282.7M |
| Working Capital Changes | $391.2M | $-74.6M | $136.8M | $86.6M |
| Cash from Operations | $29.4M | $94.1M | $196.4M | $217.8M |
| Capital Expenditures | $52.8M | $44.0M | $20.0M | $19.4M |
| Cash from Investing | $-1.06B | $-81.2M | $-51.2M | $275.1M |
| Share Buybacks | $401.5M | $0 | $0 | $363.7M |
| Cash from Financing | $520.4M | $-57.1M | $-125.6M | $-520.7M |
| FX Effect | $-30.9M | $2.8M | $-6.4M | $-300.0K |
| Net Change in Cash | $-538.8M | $-41.4M | $13.2M | $-28.1M |
| Beginning Cash | $748.4M | $209.6M | $168.2M | $181.4M |
| Ending Cash | $209.6M | $168.2M | $181.4M | $153.3M |
Frequently Asked Questions
How does MASIMO CORP make money?
Revenue is driven by the sale of Masimo Set, a subscription-based service model for disposable sensors that ensures consistent performance, and the Masimo Radical-7 and EVO-3 multi-parameter patient monitors used in critical care environments. Additional income streams include sales of reusable probes and accessories to healthcare institutions, as well as licensing revenue from technology partnerships with other medical device manufacturers.
What are the main risks for MASI?
The financial data reveals a significant one-time loss of $151.5M in the latest period due to discontinued operations, which may distort current profitability metrics and future earnings expectations. Heavy reliance on large corporate customers creates concentration risk, as any reduction in hospital capital spending or supply chain disruptions could impact revenue stability. Regulatory changes regarding medical device reimbursement rates or antitrust scrutiny of proprietary technology licensing agreements could also affect long-term growth prospects.
What is MASI's competitive advantage?
The company holds a dominant market position due to its patented RadOx™ technology which provides highly accurate readings even in challenging conditions like low perfusion or motion artifacts. MASIMO benefits from high switching costs and deep hospital integration, making it difficult for competitors to displace their established footprint in acute care settings. Strong brand recognition and a robust global distribution network provide sustained access to key healthcare procurement channels.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.